human leukocyte antigen

Overcoming barriers in treating liquid tumors with T-cell therapies 2:20
Overcoming barriers in treating liquid tumors with T-cell therapies
Michela Consonni • 1 Apr 2022
Targeting WT1 peptides for TCR-based AML therapy 2:04
Targeting WT1 peptides for TCR-based AML therapy
Chiara Bonini • 1 Apr 2022
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Characterization of ATA188: an off-the-shelf therapy for MS 4:08
Characterization of ATA188: an off-the-shelf therapy for MS
Jakob Dupont • 17 Jun 2021
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs 3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
Avoiding immune rejection of allogeneic iPSCs 3:38
Avoiding immune rejection of allogeneic iPSCs
Sonja Schrepfer • 27 May 2021
Selecting TCRs: understanding peptide-HLA-TCR interactions 6:05
Selecting TCRs: understanding peptide-HLA-TCR interactions
Dolores Schendel • 25 Feb 2021
The content of VJRegenMed is intended for healthcare professionals